Deal Watch: Amgen and Allergan Announce Positive Phase 3 Study Results for Their Avastin Biosimilar, ABP 215

Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Deal Watch  •  Market Analyses  •  U.S. FDA News

Amgen and Allergan announced their biosimilar candidate ABP 215 “met its primary and secondary endpoints” in a Phase 3 study by demonstrating “clinical equivalence in efficacy, and comparable safety and immunogenicity, to bevacizumab.”  ABP 215 is a biosimilar of Avastin (bevacizumab), a recombinant immunoglobulin G1 monoclonal antibody, for treatment of non-squamous non-small cell lung cancer in adults.  This is one of four collaborations between Amgen and Allergan on oncology-related biosimilars.

 

Read the full press release from Amgen and Allergan here.

Download PDF

Comments are closed.